Chelatec

Executive Summary

Chelatec is a French contract research organization (CRO) founded in 1999, headquartered in Grenoble, with a specialized focus on radioactive labeling and preclinical investigations. The company offers integrated services to pharmaceutical and biotechnology firms, including custom radiolabeling of biologics and small molecules, in vitro assays, and in vivo DMPK/ADME studies. Its expertise is particularly aligned with the growing field of radiopharmaceuticals and radioligands for both therapeutic and diagnostic applications. By enabling precise radiolabeling and preclinical evaluation, Chelatec supports drug developers in validating candidates before clinical translation. Operating as a private entity in the pre-clinical stage, the company benefits from increasing demand for targeted radionuclide therapies and diagnostics, driven by advances in nuclear medicine. Despite limited public information, its niche positioning in a specialized CRO segment positions it as a potential partner for radiopharma innovators. The company's long-standing presence since 1999 suggests operational stability and accumulated expertise, though growth may depend on securing larger contracts or expanding capacity. Overall, Chelatec represents a specialized service provider in a high-growth niche, with moderate near-term visibility.

Upcoming Catalysts (preview)

• Q3 2026Signing of major radiopharma development contract60% success
• TBDExpansion of radiolabeling capabilities or facility capacity50% success
• Q4 2026Partnership with academic or industry consortium for novel radioligand development40% success